CereVasc Inc, a US-based clinical-stage medical device company developing novel treatments for neurological diseases, announced on Tuesday the appointment of Shlomi Nachman and Timothy Scannell as new members of its board of directors.

Nachman has more than 25 years of experience in the medical device industry and currently serves on the boards of several medical device companies and the Arnold and Mable Beckman Foundation. Nachman has served in senior operating roles at Johnson & Johnson, where he was the company group chairman of Cardiovascular and Specialty Solutions and Vision Groups within Johnson & Johnson's Medical Devices sector. Earlier, he served in various roles with increased scope and responsibilities including worldwide president of Biosense Webster and Cordis.

Scannell has more than 30 years of experience at Stryker Corporation where he has held leadership roles including president and chief operating officer of Stryker and group president for Stryker's MedSurg & Neurotechnology businesses. He is currently a director and non-executive chairman of the board of directors for Insulet Corporation (Nasdaq:PODD) and is also a director on the boards of Novocure (Nasdaq: NVCR), Synaptive Medical, Regenity Biosciences and Molekule.